Dimethyl fumarate (DMF) is a new drug used to treat multiple sclerosis (MS) patients. Here, we examined the effects of DMF and the DMF metabolite monomethyl fumarate (MMF) on various activities of natural killer (NK) cells. We demonstrated that MMF augments the primary CD56
INTRODUCTION
Natural killer (NK) cells are large granular lymphocytes that spontaneously lyse target cells. 1 These cells can be divided into several subsets, and the most well-studied of these cells are those that either intensely or scarcely express CD56 and are referred to as CD56 bright and CD56 dim cells, respectively. 2 NK cells also have immunoregulatory features, including the secretion of cytokines and chemokines and cell-to-cell cross-talk, 3, 4 and are important in defending against viral infections and controlling tumor growth. 5, 6 The activities of NK cells are regulated through activating and inhibiting receptors, which determine the course of action of these cells. 7 NK cells are activated through distress via the detection of stress-induced ligands on target cells by NK cytotoxicity receptors, which include NKp30, NKp44, NKp46 and C-type lectin receptors, such as NKG2D. 8 In addition, NK cells express several receptors that inhibit activation, including killer cell immunoglobulin-like receptors, which interact with HLA-I molecules, and CD94-NKG2A, which interacts with HLA-E. In the absence of these 'self' ligands, NK cells are activated to kill target cells. 9 Dimethyl fumarate (DMF), also known as Tecfidera (BiogenIdec Global, Cambridge, MA, USA), is currently used to treat patients with multiple sclerosis (MS). This drug was shown to be safe for the treatment of 257 MS patients receiving high doses of DMF three times daily. 10 The mechanism of action of DMF has been attributed to the activation of Nrf2, an antioxidant transcription factor. 11, 12 Consequently, DMF protects neurons and astrocytes against oxidative stress, which induces cellular injury. 13 In addition, DMF reduces the nuclear factor NF-kB in astrocytes and C6 cells, inhibits the degradation of IkBa, and reduces the expression of nitric oxide synthase 2. 14 In the experimental autoimmune encephalomyelitis model, DMF exerts clinical effects through the reduction of macrophage-induced inflammation in the spinal cord. 15 In addition, DMF inhibits dendritic cell (DC) maturation through a reduction in the release of the inflammatory cytokines IL-6 and IL-12. 16 Ghoreschi et al. 17 observed that fumarates switch the immune system towards a Th2 type response. In addition, DMF suppresses STAT1 phosphorylation in DCs, arrests the production of type I DCs and induces the production of type II DCs, which favors the activation of Th2 cells and inhibits the expression of T-bet (Th1 cells) or RORct (Th17 cells). Interestingly, DMF might have anti-tumor effects. In an experimental model of melanoma, Loewe et al. 18 observed that DMF reduces metastases in SCID mice and inhibits the in vitro proliferation of the human melanoma cells A375 and M24met. However, the DMF metabolite monomethyl fumarate (MMF) has not been studied in detail.
We recently reported that another drug used to treat MS patients, glatiramer acetate, enhances IL-2-activated NK cell killing of K562 cells. 19 In the present study, we investigated the effects of DMF and MMF on the primary non-activated human NK cell lysis of tumor cells and the subsequent release of cytolytic molecules. We observed that MMF augments the primary CD56
1 NK cell lysis of K562 and RAJI tumor cells. We also observed that MMF enhances CD56
1 NK cell activities through the upregulation of CD107a and the release of Granzyme B. Most of these activities were inhibited through anti-NKp46, suggesting that NKp46 might mediate the effects of this metabolite.
MATERIALS AND METHODS

Culture medium and other reagents
The cells were cultured in RPMI 1640 medium supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM Lglutamine, 1% nonessential amino acids, 50 mM 2-mercaptoethanol and 10% fetal calf serum (Sigma-Aldrich, St Louis, MO, USA). Monomethyl fumarate, dimethyl fumarate and poly(styrene co-maleic acid), referred to here as maleic acid, were purchased from Sigma-Aldrich.
Cell preparation
Peripheral blood cells were collected from healthy blood bank volunteers (Ullevål Hospital, Oslo, Norway). NK cells were isolated using the RosetteSep Human NK cell Enrichment Cocktail (StemCell Technologies SARL, Grenoble, France), which removes cells positive for CD3, CD4, CD19, CD36, CD66b and glycophorin A. NK cells were further sorted into CD56
1 and CD56 2 cells through magnetic separation using the EasySep CD56 positive Selection Kit (StemCell Technologies SARL). After assessing the phenotype, the NK cells (1310 6 /ml) were incubated in the presence of 0.1, 1, 10 or 100 mM DMF or MMF (Sigma-Aldrich), or with culture medium as a control, for 24 h at 37 uC in 5% CO 2 . In some experiments, the cells were also incubated with 100 mM of maleic acid or 1000 units/ml IL-2 and examined as described below.
NK cell cytotoxicity assay
The human myeloid leukemia cell line K562 (CCL-243 obtained from American Type Culture Collection 'ATCC', Manassas, VA, USA) or RAJI human lymphoma cells (CCL-214, ATCC) were used as target cells. The target cells were incubated with 5 mg/ml calcein-AM (Sigma-Aldrich) for 1 h at 37 uC, washed and plated at 12 500 cells/well in 96-well plates. Total viability was measured in target cells incubated with culture medium only, and total cytotoxicity was measured in target cells incubated for 30 minutes with 2.5% Triton X-100. Pre-treated effector cells were plated in triplicate onto 96-well plates at the indicated effector/target (E/T) cell ratios. The plates were spun down at 500 r.p.m. for 5 min and incubated for 4 h at 37 uC in 5% CO 2 . After incubation, the cells were centrifuged, and the supernatants were removed, followed by the addition of 200 ml PBS to each well. The fluorescence intensity of the calcein-AM loaded cells was measured in a BioTek FLX TBI plate reader using 485/528 nm fluorescence filters. The percentage cytotoxicity was calculated as previously described. 20 Flow cytometric analysis CD56 1 and CD56 2 NK cells treated with 0.1, 1, 10 or 100 mM DMF or MMF, or with culture medium as a control, were extensively washed, followed by staining with surface molecule antibodies. For each treatment, 3310 5 cells were stained with 1 mg/ml FITC-conjugated mouse anti-human CD158, 1 mg/ml PE-conjugated mouse anti-human NKp30 (CD337), 1 mg/ml PE-conjugated mouse anti-human NKp44 (CD336), 1 mg/ml PE-conjugated mouse anti-human NKp46 (CD335), 1 mg/ml PE-conjugated mouse anti-human NKG2D (CD314) and FITC-conjugated or PE-conjugated mouse isotype controls (all antibodies were obtained from R&D Systems Europe, Abingdon, UK) for 45 min at 4 uC. The cells were also stained with FITC-conjugated CD107a or FITC-conjugated IgG1 isotype control (Beckton-Dickinson Pharmingen, San Diego, CA, USA). After washing twice, the cells were examined by flow cytometry (FACSC II; Becton Dickinson Biosciences, San Jose, CA, USA). Gating was performed according to the isotype control. The analysis was performed using FlowJo (Flow Cytometry Analysis Software, Ashland, OR, USA).
ELISA assay to determine the levels of Granzyme B The cells (1310 6 /ml) were incubated with 0.1, 1, 10 or 100 mM of DMF or MMF, or with culture medium as a control for 24 h at 37 uC in 5% CO 2 . In some experiments, the cells were also incubated with 100 mM maleic acid or 1000 units/ml IL-2. Subsequently, the cells were harvested, and the cell suspensions were centrifuged at 1000g for 8 min. The supernatants were collected and stored at 280 uC until further analysis. The levels of Granzyme B were measured using the human Granzyme B ELISA Kit (Bender Med Systems, Burlingame, CA, USA) according to the manufacturer's instructions. After adding TBM substrate solution, the microwell strips were incubated at room temperature in the dark for 10 min, followed by the addition of stop solution. The absorbance at 450 nm was measured on a BioTek Power Wave XS plate reader. The standard curves and concentrations were calculated using Gen5 Data Analysis Software (BioTek Instruments, Winooski, VT, USA).
Treatment with anti-NKp46 or anti-NKp30 antibodies CD56
1 NK cells (1310 6 /ml) were either left untreated or incubated with 10 mg/ml anti-NKp30 or anti-NKp46, or with 10 mg/ ml isotype IgG antibodies as a control, for 30 min. The cells were subsequently incubated with media only or with 100 mM MMF in the absence or presence of the antibodies. After 24 h, the cells were washed and examined for K562 or RAJI cell lysis and CD107a expression. In addition, the supernatants were collected from these cells, and the levels of Granzyme B were measured using ELISA. The viability was greater than 90% after incubation, as determined through the trypan blue (SigmaAldrich) exclusion test or the incorporation of calcein-AM.
Statistical analysis
Significant values were generated using several tests. In Figures 1-3 , the control and treatment groups were compared using one-way ANOVA with Dunnett's correction test for multiple comparisons. In Figure 4 , a two-way ANOVA with Bonferroni's post-hoc correction test was utilized. In certain cases, Student's t-test was also used. A P value ,0.05 was considered statistically significant. High variations among individuals were observed throughout this study. Therefore, the results from at least four donors are provided.
RESULTS
MMF augments the NK cell lysis of tumor target cells
Freshly isolated resting human blood NK cells were separated into CD56
1 and CD56 2 , incubated with various concentrations of DMF or MMF for 24 h, washed extensively and subsequently examined for the killing of leukemic cell line K562 or B-cell lymphoma RAJI cells. Figure 1a shows that DMF or MMF did not increase CD56
2 NK cell lysis of K562 cells at any concentration. Similarly, these drugs did not enhance the killing of RAJI cells (Figure 1b) . By contrast, the highest concentration of MMF (100 mM), but not DMF, enhanced CD56 
MMF increases the expression of CD107a and induces the release of Granzyme B from CD56
1 NK cells To obtain further insights into the effects of DMF and MMF on NK cell-mediated cytotoxicity, we characterized the effects of these drugs on the expression of CD107, a molecule expressed on the cell surface as a result of the release of cytolytic molecules. 21 The results demonstrated that neither DMF nor MMF affect the expression of CD107a on CD56 2 NK cells after incubation for 24 h (Figure 2a) . Intriguingly, at 100 mM, MMF significantly increased the percentages of cells expressing CD107a at 24 h post-incubation (Figure 2b ). Similar effects were observed with IL-2. Furthermore, only MMF, and not DMF or maleic acid, significantly increased the percentage of CD107a 1 cells at 24 h post-incubation (Figure 2c ). To determine whether these effects are associated with the release of cytolytic granules, we examined the effects of these drugs on the release of Granzyme B from NK cells. At all concentrations tested, neither DMF nor MMF significantly induced the release of this molecule from CD56
2 NK cells at 24 h post-incubation (Figure 2d) . However, at 100 mM, MMF significantly induced the release of Granzyme B from CD56 1 NK cells after incubation for 24 h (Figure 2e) . In experiments where controls were used, IL-2 significantly increased this release from CD56
1 NK cells (Figure 2f ). Although MMF also increased Granzyme B release, this effect was not significant, as determined through one-way ANOVA (Figure 2f) , likely reflecting the high background release of this molecule observed in these particular donors. 1 NK cells were treated for 24 h with media (Control) or with 100 mM of DMF, MMF or maleic acid and 1000 units/ml IL-2. The supernatants were collected, and the levels of Granzyme B were measured. The means6s.e.m. of four experiments performed using samples from different donors are shown. *P,0.05, **P,0.03, determined using one-way ANOVA with Dunnett's correction test. DMF, dimethyl fumarate; MMF, metabolite monomethyl fumarate; NK, natural killer.
Effects of MMF on the expression of NK cytotoxicity receptors
To correlate the killing activity with the effects of these drugs on the expression of NK cytotoxicity receptors NKp30, NKp44 and NKp46, we examined the expression of these molecules on the surface of NK cells at 24 h after incubation with MMF and DMF. Neither DMF nor MMF significantly upregulated the expression of these receptors, including NKp30, NKp44, NKp46, the killer cell immunoglobulin-like receptor CD158 or the C-type lectin NKG2D, on CD56 2 NK cells (Figure 3a) . By contrast, a significant increase in the percentage of NKp46
1
CD56
1 NK cells was observed at 24 h after incubation with 100 mM MMF, but not DMF (Figure 3b ). This effect was correlated with the mean fluorescence intensity of this molecule on the surface of CD56 1 NK cells. Treatment with 100 mM MMF, but not DMF, increased the geo mean fluorescence intensity of NKp46 on CD56 that treatment with anti-NKp46 blocked the expression of NKp46, likely reflecting the internalization of this receptor, although other mechanisms might also occur. As expected, MMF increased the expression of NKp46, whereas incubating the cells with isotype control antibody did not affect NKp46 expression, and incubation with anti-NKp46 for 30 min prior to activation with MMF inhibited the upregulation induced through this drug (Figure 4a ). Next, we investigated the effect of anti-NKp46 on the CD56
MMF increases NK cell-mediated cytolytic activity and CD107a expression through NKp46 upregulation
1 NK cell-mediated lysis of K562 cells. After 24 h stimulation, MMF increased CD56
1 NK cell lysis of K562 cells. Only treatment with anti-NKp46, but not with isotype control antibodies or anti-NKp30, significantly inhibited this activity (Figure 4b) . Similarly, MMF induced the CD56
1 NK cell lysis of RAJI cells after incubation for 24 h (Figure 4c) , and only anti-NKp46, but not anti-NKp30 or isotype control antibodies, abolished this lysis. In addition, MMF increased the percentage of CD107a 1 cells, an effect abrogated through anti-NKp46 (Figure 4d) . Surprisingly, pre-treatment with anti-NKp46 did not affect MMF-induced Granzyme B release from CD56 1 NK cells, i.e., the levels of Granzyme B were similar in MMF-and anti-NKp46-treated cells (Figure 4e) . DISCUSSION DMF has previously been used to treat psoriasis, but this drug has recently been used to treat MS patients. In randomized, double-blind, placebo-controlled DEFINE and CONFIRM studies involving patients with relapsing-remitting MS, dimethyl fumarate significantly reduced the relapse rate and improved the neuroradiological outcome compared with the , except RAJI cells were used as targets. **P,0.01 between control and cells treated with MMF, determined using two-way ANOVA with Bonferroni's post-hoc correction test. NS, not significant. Similar treatments were performed in panel (d), where the percentage of cells expressing CD107a was determined through flow cytometric analysis. *P,0.05 or **P,0.03 between control and cells treated with MMF, determined using two-way ANOVA with Bonferroni's post-hoc correction test. NS, not significant. (e) The cells were treated similarly as above, except that supernatants were collected, and the levels of Granzyme B were measured. *P,0.05 between control and cells treated with MMF as determined using two-way ANOVA with Bonferroni's post-hoc correction test. MMF, monomethyl fumarate; NK, natural killer.
placebo. 22, 23 Several mechanisms of action, such as the activation of anti-oxidants, nuclear factor (erythroid-derived 2)-like 2, [11] [12] [13] 24 or glutathione and heme oxygenase-1, have been attributed to the effects of fumarates.
14 In addition, DMF switched the immune system towards a Th2 anti-inflammatory type response through the activation of type II DCs and the suppression of type I DCs, which consequently inhibits the generation of inflammatory Th1 or Th17 cells. 17 It has been reported that DMF inhibits the proliferation of melanoma cells 18 and synergizes with dacarbazine to influence the migration of tumor cells. 25 Whether DMF or the DMF derivative MMF exerts any effect on NK cells remains unknown. We previously observed that various drugs enhance IL-2-activated NK cell lysis of tumor cells. 19, 26 However, the effects of drugs on nonactivated NK cells have not been examined, although these cells are observed under physiological conditions. Consequently, DMF or MMF might activate freshly isolated NK cells to lyse tumor cells. We observed that MMF augmented primary NK cellmediated cytolytic activity against the human chronic myelogenous leukemia cell line K562. These cells are NK-sensitive and have been used as prototypes for measuring lytic effects of NK cells against tumors. Intriguingly, MMF also induced the primary NK cell-mediated cytolysis of B lymphoma RAJI cells, which are resistant to resting NK cell-mediated cytotoxicity. Although MMF did not downregulate the killer cell immunoglobulin-like receptor CD158 expression on NK cells, this drug upregulated the expression of the NK cytotoxicity receptor NKp46, thereby shifting the threshold towards activation rather than inhibition.
The ligands for NKp46 (and NKp44) are upregulated on human glioblastoma cells infected with oncolytic herpes simplex virus. 27 This upregulation resulted in the killing of infected glioblastoma cells through NKp46-expressing NK cells. NKp46 has also been implicated in controlling tumor metastasis in animals with B16 melanoma or Lewis lung carcinoma D122. 28 Moreover, the absence of NKp46 impaired the eradication of lymphoma cells. 29 The results of the present study suggest that NKp46 is involved in these effects of MMF on NK cells, particularly after the incubation of CD56 1 NK cells with this metabolite for 24 h. Consequently, we examined the relationship between NKp46 and MMF and investigated the role of NKp46 in the MMF-induced CD56
1 -mediated lysis of K562 and RAJI cells. We observed that anti-NKp46, but not antiNKp30, inhibited MMF-induced killing of both tumor cell lines. Similarly, anti-NKp46 reversed the MMF-induced expression of CD107a in these cells. The functions of NKC receptors are not redundant, as these molecules respond differentially to multiple stimuli to eliminate target cells. 30 Intriguingly, NKp46, but not NKp30, mediates the various activities of MMF. NK cells contain several proteins, such as Granzyme and perforin, which are released upon contact with target cells, leading to the death of target cells. CD107a (also known as lysosomal-associated membrane protein-1 'LAMP-1') is present in the membranes of cytolytic granules. This molecule is expressed on the surface of CD8 1 T cells upon degranulation 31 or on NK cells following stimulation 21 and is considered a distinct marker for the cell-mediated lysis of target cells. Moreover, CD107a plays an important role in the survival of NK cells against degranulation. 32 We observed the increased expression of this CD107a on the surface of CD56
1 NK cells at 24 h post-stimulation with MMF, and this activity was closely associated with the effects of MMF on degranulation and the release of Granzyme B from CD56 1 cells, likely reflecting the ability of this drug to induce the killing of K562 and RAJI cells through CD56
1 NK cells. However, similar results were not obtained with DMF. MMF is a DMF metabolite resulting from the loss of a single methyl group through esterase-mediated hydrolysis in the intestines following oral administration of DMF. Free DMF could not be detected in the plasma of portal vein blood after the oral administration of DMF in rats, reflecting the conversion of this molecule into MMF and the formation of adducts with glutathione, 33 suggesting that MMF is the active molecule. Although DMF might be converted to MMF in vitro, the quantity of MMF generated might not be enough to induce the various activities described in the present study. Indeed, only the highest concentration of MMF, i.e., 100 mM, was effective in regulating the biological activities of NK cells.
Furthermore, MMF induces the release of cytolytic granules from NK cells for the lysis of target cells. Hence, this mechanism might not be restricted to tumor cells, but might also be applied to other NK cell targets, such as dendritic cells. Indeed, the effects of MMF on NK cells are largely similar to the effects of IL-2, which is considered the best stimulus for NK cells. However, the toxicity of IL-2 is a drawback to the use of this molecule for the treatment of cancer patients. 34 Surprisingly, anti-NKp46 did not inhibit MMF-induced Granzyme B release from NK cells, suggesting that Granzyme B release might result from other MMF activities. Consistently, it was shown that MMF is a potent agonist of hydroxycarboxylic acid receptor 2 (HCA 2 , a G protein coupled receptor; GPR109A). 35 Moreover, it was recently observed that HCA 2 mediates the therapeutic effects of DMF/MMF in mouse models of experimental autoimmune encephalomyelitis. 36 These authors showed that MMF exerts HCA 2 -dependent and HCA 2 -independent effects on various neutrophil functions. Similar mechanisms might also apply to NK cells, particularly the release of Granzyme B from these cells, explaining the differential effects of anti-NKp46, which is currently being investigated in our laboratory.
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